Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00689975
Other study ID # CDR0000588427
Secondary ID SHU-USMS-DEBRAIS
Status Completed
Phase N/A
First received June 3, 2008
Last updated August 23, 2013
Start date February 2006

Study information

Verified date December 2009
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority Unspecified
Study type Interventional

Clinical Trial Summary

RATIONALE: Studying diet and exercise interventions in overweight and obese patients with breast cancer may help doctors learn more about how to help patients lose weight and change their body composition.

PURPOSE: This randomized clinical trial is studying diet and exercise to see how well it works compared with normal care in overweight or obese women who have undergone treatment for stage I, stage II, or stage III breast cancer.


Description:

OBJECTIVES:

Primary

- To examine the effects of a dietary and exercise intervention on body weight and body composition in overweight or obese women who have undergone breast cancer treatment.

- To examine the effects of a dietary and exercise intervention on indices of psychological health status and biomarkers associated with disease recurrence in overweight or obese women who have undergone breast cancer treatment.

Secondary

- To examine the relationship between change in body weight and biomarkers associated with disease recurrence and physiological health status, including circulating levels of estrogen, C-reactive protein, and interleukin-6.

- To examine the relationship between changes in psychological health status, circulating stress hormones, and indices of immune function.

- To examine the effects of the dietary and exercise intervention on broader quality-of-life dimensions.

OUTLINE: Patients are randomized to one of intervention arms.

- Arm I (lifestyle intervention): Patients undergo moderate-intensity aerobic-exercise sessions 3 to 5 days a week for 24 weeks. Patients not able to attend five supervised sessions are counseled on how they can fit an extra 1-2 home/community-based exercise sessions into their weekly routine. All sessions of physical activity are recorded in a physical activity log. Portable pedometers are used to determine the number of steps/distance walked each day. Patients wear heart-rate monitors throughout the exercise sessions. Heart rate and ratings of perceived exertion are assessed at regular intervals. The exercise-therapy sessions use a variety of cognitive-behavioral techniques for promoting exercise adherence as well as positive attitudes and experiences.

Patients are also given individualized healthy-eating dietary advice and written information packet named ' Weight Loss On A Plate'. Patients are also counseled on how to reduce their dietary fat intake to 25% of total caloric intake, eating at least 5 portions of fruit and vegetables daily, increasing fiber intake, reducing carbohydrates, and taking moderate amounts of alcohol. Patients are also counseled on how to reduce their total daily calorie intake to 600 kcal below their calculated energy requirements. Individual energy requirements will be estimated from a formula of basal metabolic rate and physical activity level. Patients complete a 3-day diet diary prior to beginning study treatment and then weekly throughout the study. The diaries from pre-intervention and from weeks 6, 12, 18, and 24 are analyzed, looking specifically at macronutrients. Patients meet with the research assistant once weekly to discuss their individual diet diaries and identify ways in which they can further improve their nutritional intake.

- Arm II (normal care): Patients are provided with a general healthy-eating booklet entitled, "Getting the Balance Right".

Depression, psychological stress, and quality of life are assessed at baseline and then at 12 weeks, and 25 weeks.

Blood samples are examined for various biomarkers including interleukin-6 by ELISA, estradiol by radioimmunoassay, and for lymphocyte phenotyping and NK-cell activity by flow cytometry.

Salivary cortisol levels are measured 4 times on two consecutive days by high-sensitivity salivary cortisol enzyme immunoassay.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date
Est. primary completion date October 2008
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of stage I, II, or III breast cancer

- No metastatic breast cancer

- No inoperable or active loco-regional disease

- Body mass index (BMI) > 25

- Patients must have completed treatment for breast cancer within the past 3-18 months

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Female

- Menopausal status not specified

- Willing and able to attend supervised exercise sessions at least 3 times per week for a period of 24 weeks

- Patients must be an exercise pre-contemplator, contemplator, or preparer as defined by the transtheoretical model

- No physical/psychiatric impairment that would seriously impair physical mobility

- No severe nausea, anorexia, or other diseases affecting health (e.g., arthritis and multiple sclerosis)

- More than 3 months since prior exercise and not currently engaged in exercise (two or more times per week for at least 30 minutes per session)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Concurrent tamoxifen, other endocrine treatments, and trastuzumab (Herceptin®) allowed

- No concurrent alternative/complementary diets

- No concurrent high-dose antioxidant supplement therapy

- More than 4 months since prior and no concurrent hormone-replacement therapy or oral contraceptives

Study Design

Allocation: Randomized


Related Conditions & MeSH terms


Intervention

Behavioral:
behavioral dietary intervention

exercise intervention

Other:
counseling intervention

flow cytometry

immunoenzyme technique

laboratory biomarker analysis

Procedure:
complementary or alternative medicine procedure

standard follow-up care


Locations

Country Name City State
United Kingdom Sheffield Hallam University - City Campus Sheffield England

Sponsors (1)

Lead Sponsor Collaborator
Sheffield Hallam University

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Saxton JM, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V, Crank H. Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in wom — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Body weight No
Primary Body composition No
Secondary Pychological stress via the Perceived Stress Scale No
Secondary Depression via the Beck Depression Inventory II No
Secondary Cardiorespiratory fitness No
Secondary Quality of life via the FACT-G and FACT-B No
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2